Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

anacetrapib

- PMLiVE

Merck closes in on adjuvant melanoma indication for Keytruda

Its immunotherapy could catch up with BMS’ Opdivo if approved

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

MSD outlines its AI needs in tech start-up programme

Continues its Velocity Health work with Wayra UK

- PMLiVE

Amgen gets prevention claim for cholesterol drug Repatha

FDA approves new labelling on heart attack and stroke risk reduction

- PMLiVE

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

US advisors recommend GSK's shingle vaccine be used instead of Merck's rival product

AstraZeneca AZ

AZ and MSD win FDA priority review for Lynparza in breast cancer

Could become the first PARP inhibitor to be approved in the US for the disease

- PMLiVE

CETP inhibitor class finally dies as Merck abandons anacetrapib

Cholesterol drug fails to “support regulatory filings”

- PMLiVE

Merck & Co pulls out of hepatitis C R&D as market shrinks

Discontinues its new-generation treatments but Zepatier is still making headway

- PMLiVE

Keytruda adds stomach cancer to growing list of US approvals

FDA clears the drug as a third-line option after chemotherapy

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo and Yervoy ace kidney cancer trial

Combined checkpoint inhibitors show improved survival versus standard therapy

- PMLiVE

Merck & Co buys another immuno-oncology target

Will acquire German biotech Rigontec for €115m

- PMLiVE

Merck & Co’s anacetrapib data fails to generate much excitement

Treatment proves unable to reduce a composite outcome of major atherosclerotic events

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links